Leqembi is a monoclonal antibody treatment. It targets amyloid plaques in the brain. These plaques are associated with Alzheimer's disease. The drug aims to slow cognitive decline. It has shown promise in clinical trials. However, its long-term effects remain under study. Leqembi represents a advancement in Alzheimer's research. Patients and families are hopeful for improved outcomes.
The US Food and Drug Administration (FDA) has officially approved the medication Leqembi (lecanemab-irmb) for the treatment of Alzheimer's disease. While this marks a significant milestone in Alzheimer's...
On Friday, the Food and Drug Administration (FDA) approved a new drug called lecanemab, which will be marketed as Leqembi, for the treatment of Alzheimer's disease. The drug...
